Mosaic ImmunoEngineering Files 8-K
Ticker: CPMV · Form: 8-K · Filed: Jan 2, 2025 · CIK: 836564
| Field | Detail |
|---|---|
| Company | Mosaic Immunoengineering INC. (CPMV) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $15.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
TL;DR
Mosaic ImmunoEngineering filed its 8-K for year-end 2024, mostly financial docs.
AI Summary
Mosaic ImmunoEngineering, Inc. filed an 8-K report on January 2, 2025, detailing events as of December 31, 2024. The filing primarily concerns financial statements and exhibits, with no specific material events or transactions disclosed in the provided excerpt. The company, formerly known as Patriot Scientific Corp and Patriot Financial Corp, is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This 8-K filing serves as a routine update for Mosaic ImmunoEngineering, Inc., indicating the submission of financial statements and exhibits as of the end of the fiscal year.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, with no immediate indication of significant new risks or material events.
Key Players & Entities
- Mosaic ImmunoEngineering, Inc. (company) — Registrant
- Patriot Scientific Corp (company) — Former company name
- Patriot Financial Corp (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is December 31, 2024.
What is the SEC file number for Mosaic ImmunoEngineering, Inc.?
The SEC file number for Mosaic ImmunoEngineering, Inc. is 000-22182.
What was Mosaic ImmunoEngineering, Inc. formerly known as?
Mosaic ImmunoEngineering, Inc. was formerly known as Patriot Scientific Corp and Patriot Financial Corp.
In which state is Mosaic ImmunoEngineering, Inc. incorporated?
Mosaic ImmunoEngineering, Inc. is incorporated in Delaware.
What is the primary purpose of this 8-K filing based on the provided information?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of December 31, 2024.
Filing Stats: 769 words · 3 min read · ~3 pages · Grade level 13.6 · Accepted 2025-01-02 09:15:32
Key Financial Figures
- $15.0 million — ic shares of its common stock valued at $15.0 million upon execution of the definitive agreem
Filing Documents
- mosaic_8k.htm (8-K) — 30KB
- mosaic-ex1001.htm (EX-10.1) — 7KB
- image_005.jpg (GRAPHIC) — 9KB
- 0001683168-25-000009.txt ( ) — 215KB
- cpmv-20241231.xsd (EX-101.SCH) — 3KB
- cpmv-20241231_lab.xml (EX-101.LAB) — 33KB
- cpmv-20241231_pre.xml (EX-101.PRE) — 22KB
- mosaic_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events As previously reported on Form 8-K on April 29, 2024, Mosaic ImmunoEngineering, Inc. a Delaware corporation (the "Company" or "Mosaic"), entered into a binding term sheet on April 26, 2024 (the "Binding Term Sheet") with Oncotelic Therapeutics, Inc. ("Oncotelic") whereby the Company intends to acquire certain rights to technologies from Oncotelic, including its clinical stage necroptosis cancer therapies associated with Oncotelic's vascular disruptive agents ("VDAs") and related regulatory and clinical packages. The Company will also have access to Oncotelic's proprietary Artificial Intelligence ("AI") technologies for identifying immunotherapy combinations. In exchange for the rights to these technologies, the Company would issue Oncotelic shares of its common stock valued at $15.0 million upon execution of the definitive agreement, or a combination common stock and preferred stock to be determined by the parties, along with additional milestones allowing Oncotelic to earn up to an additional $15.0 million in shares of common stock that would be valued at the time of issuance, if earned. Pursuant to the Binding Term Sheet, the parties agreed to negotiate in good faith towards the execution of the definitive agreement and the closing of the transactions contemplated thereby, which will be subject to customary due diligence and other conditions as described in the Binding Term Sheet. On December 31, 2024, the Company and Oncotelic agreed to extend the expiration date to June 30, 2025 to allow additional time to enter into a possible transaction under the Binding Term Sheet. The Company and Oncotelic are continuing to pursue a potential transaction under the Binding Term Sheet although there are no guarantees we will enter into any definitive agreement. A copy of the letter extending the term is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K. The information in this Item 8.01, including Exhibit 10.1 attached hereto, is b
Financial Statements and Exhibits
Financial Statements and Exhibits (d) The following exhibits are being filed herewith: Exhibit No. Description 10.1 Term Extension Letter dated December 31, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mosaic ImmunoEngineering, Inc. Date: January 2, 2025 By: /s/ Steven King Steven King President and Chief Executive Officer, Director 3